Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.

Wataru FukuokayaTakahiro KimuraTakafumi YanagisawaShoji KimuraShunsuke TsuzukiYuhei KoikeYuya IwamotoYuki EneiMasatoshi TanakaFumihiko UrabeHajime OnumaMariko HondaJun MikiYu OyamaHirokazu AbeShin Egawa

Published in: BJU international (2020)

Compared with RECIST, iRECIST could more accurately predict OS of patients with metastatic UC treated with pembrolizumab. The iRECIST has the potential to be a new standard for tumour response evaluation of these patients.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
advanced non small cell lung cancer
prognostic factors
peritoneal dialysis